… ment of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm shift in … cell
lung cancer (NSCLC). For advanced NSCLC harboring activating EGFR mutations, an EGFR-TKI …

… In China, it is also the most common cancer and leading cause of cancer-related … (EGFR)
mutations. NSCLC harboring EGFR mutations constitutes about 10–20% of all lung cancer …

… EGFR mutations in patients, our understanding of the biology of these … EGFR mutations is
poor compared to classical mutations. In particular, clinical data focused on these mutations is …

… with metastatic EGFR exon19del or L858R-mutant lung cancers treated with first/second-generation
EGFR … EGFR wild-type lung adenocarcinoma samples were used for comparison. …

… -target EGFR kinase mutations. We discuss array of mutations, their structural effects on the
EGFR … strategies to overcome the individual resistance profiles found in lung cancer patients. …

… The results of this study suggest that EGFR mutant subtypes of non-small-cell lung cancer
have distinct response to immune checkpoint inhibitors and distinct tumor mutation burdens. …

… mutation. However, the clinical or prognostic implications of EGFR mutation status in surgically
resected lung cancers … We hypothesized that EGFR mutation status and mutation subtypes…

… patients with lung cancer carrying EGFR mutations. Genetic … lung cancer disease and
tracking the clonal evolution could be the way to individualise the further target treatments in EGFR…

Background Osimertinib is standard-of-care therapy for previously untreated epidermal
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer (NSCLC). …

… We reviewed the medical records of all patients with EGFR mutation–positive advanced or
… EGFR mutations were detected with commercial assays such as the cobas EGFR Mutation …